CD82 antigen (CD82) (CD82)

CD82 antigen (CD82), also known as KAI1, is a member of the tetraspanin superfamily of transmembrane proteins that plays a critical role in regulating cell-cell and cell-matrix interactions (UniProt: P27701). It is widely recognized as a potent metastasis suppressor, as its expression is frequently downregulated during the progression of various solid tumors, including prostate, lung, and breast cancers (PubMed: 7754374). CD82 functions by organizing tetraspanin-enriched microdomains (TEMs) on the cell surface, where it interacts with integrins, growth factor receptors, and other signaling molecules to inhibit cell motility and invasion (PubMed: 22532583). In the immune system, CD82 associates with MHC molecules and co-receptors like CD4 and CD8 to modulate T-cell activation and antigen presentation (PubMed: 15155618). While no drugs targeting CD82 are currently FDA-approved, therapeutic strategies under investigation include the restoration of CD82 expression via gene therapy or the use of monoclonal antibodies to stabilize its function (PubMed: 28651543). Its role as a prognostic biomarker is well-established, with low CD82 levels correlating with poor clinical outcomes and increased metastatic potential in oncology patients (NCBI Gene: 963).

Other names

KAI1TSPAN27Metastasis suppressor protein KAI1Tetraspanin-27C33 antigenR2IA4ST6GR15SAR2

Restoration or stabilization of CD82-mediated tetraspanin-enriched microdomains (TEMs) to suppress tumor cell migration and invasion (PubMed: 22532583).